sacituzumab govitecan,durvalumab
gilead sciences,medimmune,astrazeneca
['neostar', 'nsclc', 'sclc']
#sitc is at #asco22 checking out the io presos. dr. tina cascone shared about benefits and bio markers associated w/ neoadjuvant comb. therapies, results from neostar trial and neocoast trial investigation combination therapy for nsclc. #immune2cancer #cim22 
Society for Immunotherapy of Cancer (SITC) - Dedicated to improving cancer patient outcomes by advancing the field of tumor immunology and cancer immunotherapy.